article thumbnail

STAT+: Cancer therapy’s new ‘gold rush’:  bispecific antibodies that hit key combination of targets

STAT

” Experts told STAT there’s been a surge of interest for these compounds from biotech and pharma in the last few months, spurred on most by the presentation of promising clinical data from Summit Therapeutics.

article thumbnail

STAT+: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list

STAT

A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: We’re watching a ban compounded versions of GLP-1s, a Biogen acquisition, and more

STAT

Data presented this week at the Digestive Disease Week meeting in D.C. Australia to ban compounded versions of blockbuster drugs Ozempic and Mounjaro, Reuters reports. A drug often used off-label to treat alcohol use disorder might provide better benefits than therapies approved for this indication, STAT tells us.

article thumbnail

STAT+: Pharmalittle: We’re reading about copycat weight loss drugs, ADHD prescriptions spiking, and more

STAT

Food and Drug Administration wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies that have fueled widespread use of the knockoffs have other plans , The Wall Street Journal writes. And some pharmacies making the GLP-1 drug copycats will continue.

article thumbnail

STAT+: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more

STAT

So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. … A trade group representing large compounding pharmacies has sued the U.S. We trust you have your own hectic agendas. Have a grand day, everyone, and do stay in touch.

article thumbnail

STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments

STAT

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting , a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

article thumbnail

STAT+: Pharmalittle: We’re reading about a cancer therapy’s gold rush, FDA warning Sanofi, and more news

STAT

There has been a surge of interest in these compounds from biotech and pharma in the last few months, spurred on most by the presentation of promising clinical data from Summit Therapeutics.